Rosetta Biosoftware and Agilent Technologies Release Rosetta Luminator System Version 2.0.

Business Editors/Health/Medical Writers/High-Tech Writers

KIRKLAND, Wash. & PALO ALTO, Calif.--(BUSINESS WIRE)--July 8, 2003

New Rosetta Luminator(TM) system provides significant product

enhancements to accelerate gene expression research in

small- to mid-sized research labs

Rosetta Biosoftware and Agilent Technologies Inc. (NYSE:A) today announced the introduction of the Rosetta Luminator system version 2.0, a client-server bioinformatics system for storing and analyzing microarray data.

The Rosetta Luminator system provides an affordable enterprise solution with the advanced analysis features and performance needed by small to mid-size commercial or academic gene expression research efforts. Developed by Rosetta Biosoftware, the Rosetta Luminator system is distributed exclusively by Agilent as an integral part of Agilent's complete gene expression solution offering for life science researchers.

The Rosetta Luminator system benefits from the technology enhancements of the highly scalable and customizable Rosetta Resolver(R) system. The Rosetta Resolver system has been selected as the global gene expression bioinformatics solution by leading pharmaceutical, biotechnology and academic organizations.

Version 2.0 of the Rosetta Luminator system expands its suite of data management and analysis features to include the following new benefits:

-- ANOVA (Analysis of Variance) -- Study variations between

different experiments using advanced patent-pending

transformation algorithms that increase the sensitivity and

specificity of analysis results;

-- Bayesian Classifiers -- Characterize unknown data sets

leveraging prior knowledge, enabling such analyses as

predicting phenotype, toxicological effect, class or clinical

outcome of an unknown sample;

-- PCA (Principal Component Analysis) -- Determine the genes or

experiments contributing most significantly to the variation

within the data set and reduce the dimensionality of the data

when clustering large data sets for greater performance.

The Rosetta Luminator system provides a centralized Oracle(R) database to warehouse all microarray data and relevant experiment annotations. The system's annotative laboratory information management system (LIMS) capabilities enable customers to import and store information related to their gene expression experiments and conduct gene expression data analysis using advanced error models and research tools.

"The powerful analytical enhancements included with the Rosetta Luminator system version 2.0, in addition to the increased data management capacity and performance, provide small- to mid-size organizations with a turn-key solution for gene expression data warehousing and analysis," said Douglas E. Bassett, Jr., Ph.D., vice president and general manager of Rosetta Biosoftware. "Whether it is an academic core facility or a commercial biotechnology company, the Rosetta Luminator system provides an economical means by which they can achieve their expression research goals."

"This new version of the Rosetta Luminator system is a powerful yet cost-effective enterprise gene expression data analysis system that helps life scientists to accelerate their microarray-based research and drug discovery efforts," said Barney Saunders, general manager and vice president of Agilent's BioResearch Solutions unit. "We are pleased to include the Rosetta Luminator system as an important component of our complete gene expression solution, which is based on an integrated, flexible and modular approach to successful gene expression analysis."

About the Rosetta Luminator System

The Rosetta Luminator system provides an affordable solution for gene expression warehousing and analysis with the advanced features and performance needed by a small- to mid-size commercial or academic department level gene expression research effort. The Rosetta Luminator system is designed to grow with the needs of the gene expression researcher and provides a seamless upgrade path to Rosetta Biosoftware's flagship enterprise gene expression data analysis product, the Rosetta Resolver system. Additional information about the Rosetta Luminator system can be found on the Rosetta Biosoftware Web site at www.rosettabio.com/products/luminator or by contacting your local Agilent representative at [e-mail].

About Agilent Technologies

Agilent Technologies Inc. (NYSE:A) is a global technology leader in communications, electronics, life sciences and chemical analysis. The company's 35,000 employees serve customers in more than 110 countries. Agilent had net revenue of $6 billion in fiscal year 2002. Information about Agilent is available on the Web at www.agilent.com.

About Rosetta Biosoftware

Rosetta Biosoftware is a leading provider of enterprise bioinformatics solutions for life science research. Its enterprise software solutions, including the Rosetta Resolver and Rosetta Luminator gene expression data analysis systems, are designed to empower researchers to accelerate discovery with advanced, scalable, and easy-to-use analysis technology. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a wholly-owned subsidiary of Merck & Co., Inc. (NYSE:MRK). For more information on Rosetta Biosoftware, please visit www.rosettabio.com.

Rosetta Inpharmatics Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this document should be evaluated together with the many uncertainties that affect the business of Merck & Co., Inc. including, among others, the extent to which Rosetta Inpharmatics' technology platform can be used in drug discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics' technologies, ability to compete against existing technologies and those uncertainties mentioned in the cautionary statements in Item 1 of Merck & Co., Inc.'s Form 10-K for the year ended December 31, 2002, and in Merck & Co., Inc.'s periodic reports on Form 10-Q and Form 8-K (if any), which we incorporate by reference.

Resolver and Luminator are trademarks or registered trademarks of Rosetta Inpharmatics LLC. Oracle is a U.S. registered trademark of Oracle Corporation, Redwood City, California.